Analog Devices R&D increased by 9.0% to $509.32M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.3%, from $441.84M to $509.32M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 8.0% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $302.24M | $306.62M | $399.12M | $426.78M | $420.90M | $431.83M | $421.01M | $414.10M | $415.75M | $423.75M | $406.59M | $391.43M | $354.86M | $362.67M | $378.90M | $402.89M | $441.84M | $454.25M | $467.02M | $467.40M | $509.32M |
| QoQ Change | — | +1.4% | +30.2% | +6.9% | -1.4% | +2.6% | -2.5% | -1.6% | +0.4% | +1.9% | -4.0% | -3.7% | -9.3% | +2.2% | +4.5% | +6.3% | +9.7% | +2.8% | +2.8% | +0.1% | +9.0% |
| YoY Change | — | — | — | — | +39.3% | +40.8% | +5.5% | -3.0% | -1.2% | -1.9% | -3.4% | -5.5% | -14.6% | -14.4% | -6.8% | +2.9% | +24.5% | +25.3% | +23.3% | +16.0% | +15.3% |
| Segment | Q2 '26 |
|---|---|
| Reportable Segment | $150.19M |
| Total | $509.32M |